Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Frontiers in oncology, 10, Article 1115, S. 1115-1-1115-11
- Ereignis
-
Veröffentlichung
- (wo)
-
Bochum
- (wer)
-
Ruhr-Universität Bochum
- (wann)
-
2020
- Urheber
-
Klein-Scory, Susanne
Wahner, Ingo
Maslova, Marina
Al-Sewaidi, Yosef
Pohl, Michael
Mika, Thomas
Ladigan, Swetlana
Schroers, Roland
Baraniskin, Alexander
- URN
-
urn:nbn:de:hbz:294-75906
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Klein-Scory, Susanne
- Wahner, Ingo
- Maslova, Marina
- Al-Sewaidi, Yosef
- Pohl, Michael
- Mika, Thomas
- Ladigan, Swetlana
- Schroers, Roland
- Baraniskin, Alexander
- Ruhr-Universität Bochum
Entstanden
- 2020
Ähnliche Objekte (12)
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
Pembrolizumab as first-line treatment for metastatic uveal melanoma
MEK targeting in N-RAS mutated metastatic melanoma
Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
RAS testing in metastatic colorectal cancer: advances in Europe
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
Pembrolizumab as first-line treatment for metastatic uveal melanoma
MEK targeting in N-RAS mutated metastatic melanoma
Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
RAS testing in metastatic colorectal cancer: advances in Europe
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
Pembrolizumab as first-line treatment for metastatic uveal melanoma
MEK targeting in N-RAS mutated metastatic melanoma
Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
RAS testing in metastatic colorectal cancer: advances in Europe
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment